1. Диагностика и лечение стабильной стенокардии. Российские рекомендации, второй пересмотр. Кардиоваскул. тер. и проф. 2008; 7 (6): прил. 4.
2. Bulkely BH, Hutchins GM. Myocardial consequences of coronary artery bypass graft surgery. The paradox of necrosis in areas of revascularization. Circulation 1977; 56: 906–13.
3. Carden DL, Granger DN. Pathophysiology of ischemia-reperfusion injury. J Pathol 2000; 190: 255–66.
4. Hoffman JW, Gilbert TB, Poston RS, Silldorff EP. Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol 2004; 36: 391–411.
5. Moens AL, Claeyes MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion injury, a clinical view on a complex pathophysiological process. Int J Cardiol 2005; 100: 179–90.
6. Kantor PF, Lucien A, Kozak R, Lopashuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580–8.
7. Williams FM, Tanda K, Kus M, Williams T. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828–33.
8. Tritto I, Ambrosio G et al. The Anti-Anginal Drug Trimetazidine Reduces Neutrophil-Mediated Cardiac Reperfusion Injury J Cardiovasc Pharmacol 2005; 46: 89–98.
9. Argaud L, Gomes L, Gateau-Roesch O et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39: 983–99.
10. Ruixing Y, Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 2007; 149: 152–60.
11. Gupta R, Sawhney JPS, Narain VS. Treatment of Stable Angina Pectoris with Trimetazidine Modified Release in Indian Primary-Care Practice. Am J Cardiovasc Drugs 2005; 5 (5): 325–9.
12. Kober G, Pennaforte S, Buck T et al. Myocardial cytoprotection during percutaneous transluminal coronary angioplasty. Eur Heart J 1993; 14 (suppl. G): 6–11.
13. Steg PG, Grollier G, Gallay P et al. for the LIST study Group. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001; 77: 263–73.
14. Polonski L, Dec I, Wojnar R, Wilczek K. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin 2002; 18: 389–96.
15. Bonello M, Sbragia P, Amabile N et al. Protective effect of an acute oral loading dose of Trimetazidine on myocardial injury following percutaneus coronary intervention. Heart 2007; 93: 703–7.
16. Fabiani JN, Ponzio O, Emerit I et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992; 23: 486–91.
17. Vedrinne JM, Vedrinne C, Bompard D et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 1996; 82: 712–8.
18. Tunerir В, Colak О, Alatas О et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68: 2173–6.
19. Ruzyllo W, Szwed H, Sadowski Z et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004; 20: 1447–54.
20. Labrou A, Giannoglou G, Ziotas D et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007; 7: 143–50.
21. Лопатин Ю.М., Дронова Е.П. Клинико-фармакоэкономические аспекты применения триметазидина модифицированного высвобождения у больных ишемической болезнью сердца, подвергнутых коронарному шунтированию. Кардиология. 2009; 2: 15–21.